Additional Features in the Treatment of Patients with Chronic Heart Failure. From EMPA-REG OUTCOME Study to EMPEROR-REDUCED Study. Resolution of the On-line Scientific Meeting of Moscow Experts

Additional Features in the Treatment of Patients with Chronic Heart Failure. From EMPA-REG OUTCOME Study to EMPEROR-REDUCED Study. Resolution of the On-line Scientific Meeting of Moscow Experts

The results of the international multicenter study EMPEROR-REDUCED were reviewed the on-line scientific meeting of Moscow experts on October 30, 2020. Some proposals and recommendations for further study of the cardiovascular and renal effects of empagliflozin and its use in clinical practice in pat...

Full description

Bibliographic Details
Main Authors: A. Yu. Lebedeva, O. M. Koteshkova, O. N. Dzhioeva, S. R. Gilyarevsky, T. M. Uskach, M. S. Novikova, Ya. A. Orlova, V. Yu. Kalashnikov, D. V. Privalov, N. A. Ananicheva, M. Yu. Gilyarov, A. D. Erlikh
Format: Article
Language:English
Published: Столичная издательская компания 2021-03-01
Series:Рациональная фармакотерапия в кардиологии
Subjects:
empagliflozin
chronic heart failure
cardiovascular mortality
chronic kidney disease
emperor-reduced study
Online Access:https://www.rpcardio.online/jour/article/view/2402

Internet

https://www.rpcardio.online/jour/article/view/2402

Similar Items